Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of BT02 in advanced solid tumors
CTR20240083Phase 2Active
- Sponsor
- Boquan Biotech
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BT02 in Nonhematologic neoplasms, sponsored by Boquan Biotech. Started Feb 2024; status: active.
02
Drugs
BT02
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20240083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240083.